Artwork

Contenuto fornito da Labiotech. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Labiotech o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !

How biotech is tackling myasthenia gravis

28:50
 
Condividi
 

Manage episode 419977836 series 3361449
Contenuto fornito da Labiotech. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Labiotech o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the skeletal muscles.

It especially affects the voluntary muscles of the eyes, mouth, throat and/or limbs. It is most frequent in women from 20 and 30 and men aged 50 and older.

To talk about the disease, how it is being treated, and what is in the pipeline for future treatments, we had a conversation with Dana Vigier, head of Central Eastern and Northern Europe at Alexion.

01:07-04:26: Background on Dr Dana Vigier
04:26-07:07: What is myasthenia gravis?
07:07-09:43: What is the prognosis for someone diagnosed with myasthenia gravis?
09:43-11:33: How effective are current treatments for myasthenia gravis?
11:33-12:56: Do all the myasthenia gravis drugs work in the same way?
12:56-18:35: What R&D is taking place in myasthenia gravis?
18:35-21:14: Alexion and its work on myasthenia gravis
21:14-22:01: Myasthenia gravis clinical trials
22:01-23:58: The importance of myasthenia gravis awareness month
23:58-25:31: Would early diagnosis make a difference?
25:31-27:54: Transformation through new treatments
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Capitoli

1. How biotech is tackling myasthenia gravis (00:00:00)

2. Background on Dr Dana Vigier
 (00:01:07)

3. What is myasthenia gravis?
 (00:04:26)

4. What is the prognosis for someone diagnosed with myasthenia gravis?
 (00:07:07)

5. How effective are current treatments for myasthenia gravis?
 (00:09:43)

6. Do myasthenia gravis drugs work in the same way? 
 (00:11:33)

7. What R&D is taking place in myasthenia gravis?
 (00:12:56)

8. Alexion and its work on myasthenia gravis
 (00:18:35)

9. Myasthenia gravis clinical trials
 (00:21:14)

10. The importance of myasthenia gravis awareness month
 (00:22:01)

11. Would early diagnosis of myasthenia gravis make a difference? (00:23:58)

12. Transformation through new treatments (00:25:31)

110 episodi

Artwork
iconCondividi
 
Manage episode 419977836 series 3361449
Contenuto fornito da Labiotech. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Labiotech o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the skeletal muscles.

It especially affects the voluntary muscles of the eyes, mouth, throat and/or limbs. It is most frequent in women from 20 and 30 and men aged 50 and older.

To talk about the disease, how it is being treated, and what is in the pipeline for future treatments, we had a conversation with Dana Vigier, head of Central Eastern and Northern Europe at Alexion.

01:07-04:26: Background on Dr Dana Vigier
04:26-07:07: What is myasthenia gravis?
07:07-09:43: What is the prognosis for someone diagnosed with myasthenia gravis?
09:43-11:33: How effective are current treatments for myasthenia gravis?
11:33-12:56: Do all the myasthenia gravis drugs work in the same way?
12:56-18:35: What R&D is taking place in myasthenia gravis?
18:35-21:14: Alexion and its work on myasthenia gravis
21:14-22:01: Myasthenia gravis clinical trials
22:01-23:58: The importance of myasthenia gravis awareness month
23:58-25:31: Would early diagnosis make a difference?
25:31-27:54: Transformation through new treatments
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Capitoli

1. How biotech is tackling myasthenia gravis (00:00:00)

2. Background on Dr Dana Vigier
 (00:01:07)

3. What is myasthenia gravis?
 (00:04:26)

4. What is the prognosis for someone diagnosed with myasthenia gravis?
 (00:07:07)

5. How effective are current treatments for myasthenia gravis?
 (00:09:43)

6. Do myasthenia gravis drugs work in the same way? 
 (00:11:33)

7. What R&D is taking place in myasthenia gravis?
 (00:12:56)

8. Alexion and its work on myasthenia gravis
 (00:18:35)

9. Myasthenia gravis clinical trials
 (00:21:14)

10. The importance of myasthenia gravis awareness month
 (00:22:01)

11. Would early diagnosis of myasthenia gravis make a difference? (00:23:58)

12. Transformation through new treatments (00:25:31)

110 episodi

Tutti gli episodi

×
 
Loading …

Benvenuto su Player FM!

Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.

 

Guida rapida